Goldman Sachs Highlights BioNTech's (BNTX) Immuno-Oncology and ADC Pipeline

BioNTech SE (NASDAQ:BNTX) ranks among the best high growth European stocks to buy. On January 16, Goldman Sachs upgraded BioNTech SE (NASDAQ:BNTX) from Neutral to Buy and boosted its price target from $115 to $142, highlighting the company’s key position in oncology. According to the firm, BioNTech SE (NASDAQ:BNTX) stands “at the nexus of significant developments occurring in the oncology field,” particularly in next-generation immuno-oncology and antibody-drug conjugates (ADCs).

Goldman Sachs noted BioNTech’s extensive portfolio of programs aimed at an estimated market worth more than $100 billion, with key results coming in 2026 that could position the company as a pioneer in the next stage of oncology treatments.

However, Goldman Sachs recognized potential rivalry in BioNTech’s clinical development domains, including competition from other bispecific antibody companies and late-stage ADC initiatives. However, it determined that BioNTech has a “unique risk/reward opportunity” in the rapidly changing oncology field.

BioNTech SE (NASDAQ:BNTX) is a German biotechnology company that develops and commercializes novel immunotherapies and vaccines for cancer and infectious diseases.

While we acknowledge the potential of BNTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This article is originally published at Insider Monkey.